A 6-week Open-label, Randomised, Multicentre, Phase IIIb, Parallel-group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) with Atorvastatin (20 mg) in Subjects with Hypercholesterolaemia and Either a History of Coronary Heart Disease (CHD) or Clinical Evidence of Atherosclerosis or a CHD Risk Equivalent (10-year Risk Score of >20%)

Trial Profile

A 6-week Open-label, Randomised, Multicentre, Phase IIIb, Parallel-group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) with Atorvastatin (20 mg) in Subjects with Hypercholesterolaemia and Either a History of Coronary Heart Disease (CHD) or Clinical Evidence of Atherosclerosis or a CHD Risk Equivalent (10-year Risk Score of >20%)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2008

At a glance

  • Drugs Atorvastatin; Rosuvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms PULSAR
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top